Drugs.com Clinical Trial ResultsOriginal article
Johnson & Johnson Investigational Co-Antibody Therapy JNJ-4804 Shows Potential to Raise the Bar for Clinical Efficacy in Treating Refractory Inflammatory Bowel Disease
Phase 2positiveJNJ-4804Positive
AI Analysis
Summary
Johnson & Johnson announced positive Phase 2b data for JNJ-4804, an investigational co-antibody therapy dual-targeting IL-23 and TNF, in patients with refractory inflammatory bowel disease. The data suggests the therapy has potential to improve clinical efficacy in this difficult-to-treat patient population.
Clinical Trial Data
Phase
2b
Outcome Details
Phase 2b data from two studies showing potential to raise the bar for clinical efficacy
Importance:6/10
Sentiment:
0.70
Phase 2binflammatory bowel diseaseco-antibody therapyIL-23TNF
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on May 5, 2026 2:05 AM